Immune gene profiling of pretreatment tumor samples in "real-world" advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.9585
Abstract: 9585Background: The immune checkpoint inhibitors (CI) anti-CTLA-4 (ipilimumab [IPI]) and anti-PD-1 (pembrolizumab [PEM] and nivolumab [NIVO]) have improved survival in advanced melanoma patients (p... read more here.
Keywords: anti ctla; advanced melanoma; gene profiling; profiling pretreatment ... See more keywords